The Enhanced Cytotoxic Effects of the p28-Apoptin Chimeric Protein As A Novel Anti-Cancer Agent on Breast Cancer Cell Lines

Abstract

Backgrounds Peptide-based drugs have shown promising results in overcoming the limitations of chemotherapeutic drugs by providing a targeted therapy approach to cancer. However, the response rate of targeted therapies is limited, in large part due to the intra- and inter-heterogeneity of tumors.

Methods In this study, we engineered a novel chimeric protein composed of the p28 peptide as a tumor-homing killer peptide and apoptin as a killer peptide. We evaluated its cytotoxicity against MCF7 and MDA-MB-231 breast cancer cells and HEK-293 normal cells by the MTT assay. Different linkers were evaluated when designing the chimeric protein. Three-dimensional structure predictions of chimeric proteins with different linkers were carried out by Modeller 9.19, and their validation and analysis were performed by RAMPAGE.

Results Results showed that a cleavable linker, including furin cleavage sites, is preferred over other linkers. The chimeric protein was then successfully expressed in E. coli and purified by affinity chromatography under native conditions, then confirmed by SDS-PAGE and Western blot analysis. Compared with apoptin alone, the chimeric protein showed significantly higher toxicity against breast cancer cell lines in a dose-dependent manner. The IC₅₀ values of the chimeric protein for MCF7 and MDA-MB-231 cells were 38.55 µg/mL and 43.11 µg/mL, respectively. There was no significant cytotoxic effect on the normal HEK293 cell line.

Conclusion This study demonstrates that fusion of p28 peptide to a potent protein could provide an effective method for tumor targeting. Further, in vitro and in vivo studies of this novel chimeric protein are underway.

Key words

Selective tumor targeting - p28 peptide - Apoptin - Breast cancer

• References

• 1 Szakacs G, Paterson JK, Ludwig JA. et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234
• 2 Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Canc Ther Rev 2006; 2: 271-279
• 3 Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology 2015; 29: 282-294
• 4 Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev 2015; 795602
• 5 Floyd J, Mirza I, Sachs B. et al. Hepatotoxicity of chemotherapy. Semin Oncol. 2006; 33: 50-67
• 6 Buyukpamukcu M, Varan A, Yazici N. et al. Second malignant neoplasms following the treatment of brain tumors in children. Send to J Child Neurol 2006; 21: 433-436
• 7 Lee SH, Shin CH. Reduced male fertility in childhood cancer survivors. Ann Pediatr Endocrinol Metab 2013; 18: 168-172
• 8 Pachmayr E, Treese C, Stein U. Underlying Mechanisms for Distant Metastasis - Molecular Biology. Visc Med 2017; 33: 11-20
• 9 Burrell RA, Swanton C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8: 1095-1111
• 10 Bayat Mokhtari R, Homayouni TS, Baluch N. et al. Combination therapy in combating cancer. Oncotarget 2017; 8: 38022-38043
• 11 Yavari B, Mahjub R, Saidijam M et al. The potential use of peptides for cancer treatment. Current Protein & Peptide Science 2018 Jan 11
• 12 King A, Ndifon C, Lui S. et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv 2016; 2: e1600349
• 13 Thundimadathil J. Cancer treatment using peptides: Current therapies and future prospects. J Amino Acids 2012; 2012: 967347
• 14 Yamada T, Das Gupta TK, Beattie CW. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation. Mol Pharm 2013; 10: 3375-3383
• 15 Yamada T, Christov K, Shilkaitis A. et al. p28, a first in class peptide inhibitor of cop1 binding to p53. Br J Cancer 2013; 108: 2495-2504
• 16 Oorschot AAAMD-V, Fischer DF, Grimbergen JM. et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proceedings of the Proc Natl Acad Sci U S A 1997; 94: 5843-5847
• 17 Teodoro JG, Heilman DW, Parker AE. et al. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev 2004; 18: 1952-1957
• 18 Olijslagers SJ, Zhang YH, Backendorf C. et al. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 2007; 100: 127-131
• 19 Tavassoli M, Guelen L, Luxon BA. et al. Apoptin: Specific killer of tumor cells?. Apoptosis 2005; 10: 717-724
• 20 Wadia JS, Wagner MV, Ezhevsky SA. et al. Apoptin/VP3 contains a concentration-dependent nuclear localization signal (NLS), not a tumorigenic selective NLS. J Virol 2004; 78: 6077-6078
• 21 Ozaki T, Nakagawara A. Role of p53 in Cell Death and Human Cancers. Cancers 2011; 3: 994-1013
• 22 Bedard PL, Hansen AR, Ratain MJ. et al. Tumour heterogeneity in the clinic. Nature 2013; 501: 355-364
• 23 Bozic I, Reiter JG, Allen B. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013; 2: e00747
• 24 Warso MA, Richards JM, Mehta D. et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer 2013; 108: 1061-1070
• 25 Soleimani M, Mirmohammad-Sadeghi H, Sadeghi-Aliabadi H. et al. Expression and purification of toxic anti-breast cancer p28-NRC chimeric protein. Adv Biomed Res 2016; 5: 70
• 26 Zhang J, Yun J, Shang Z. et al. Design and optimization of a linker for fusion protein construction. Prog Nat Sci 2009; 19: 1197-1200
• 27 Soleimani M, Mahnam K, Mirmohammad-Sadeghi H. et al. Theoretical design of a new chimeric protein for the treatment of breast cancer. Res Pharm Sci 2016; 11: 187-199
• 28 Agha Amiri S, Shahhosseini S, Zarei N. et al. A novel anti-CD22 scFv-apoptin fusion protein induces apoptosis in malignant B-cells. AMB Express 2017; 7: 112
• 29 Sun J, Yan Y, Wang XT. et al. PTD4-apoptin protein therapy inhibits tumor growth in vivo. International Journal of Cancer 2009; 124: 2973-2981
• 30 Wang T, Zhao J, Ren JL. et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Research 2007; 67: 11830-11839